This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALBO Albireo Pharma (ALBO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Albireo Pharma Stock (NASDAQ:ALBO) 30 days 90 days 365 days Advanced Chart Get Albireo Pharma alerts:Sign Up Key Stats Today's Range$43.99▼$44.9050-Day Range$43.50▼$44.9552-Week Range$16.02▼$45.23Volume1.24 million shsAverage Volume704,539 shsMarket Capitalization$913.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. Read More Receive ALBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ALBO Stock News HeadlinesAlbireo Launches Critical Alarm Management Service for Mission Critical Buildings that Require Uptime and ReliabilityMay 6, 2024 | businesswire.comProspect Park II in Fort LauderdaleJanuary 19, 2024 | bizjournals.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.August 8 at 2:00 AM | Brownstone Research (Ad)ALBO Historical DataOctober 1, 2023 | investing.comIpsen Pharma: Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolioMarch 4, 2023 | finanznachrichten.deALBO Albireo Pharma, Inc.February 25, 2023 | seekingalpha.comAlbireo Pharma, Inc. (ALBO)February 18, 2023 | uk.finance.yahoo.comAlbireo Gets FDA Priority Review of Bylvay in Alagille Syndrome >ALBOFebruary 14, 2023 | marketwatch.comSee More Headlines ALBO Stock Analysis - Frequently Asked Questions How were Albireo Pharma's earnings last quarter? Albireo Pharma, Inc. (NASDAQ:ALBO) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $3.28. The biopharmaceutical company had revenue of $3.66 million for the quarter, compared to analyst estimates of $22.33 million. Albireo Pharma had a negative net margin of 228.51% and a negative trailing twelve-month return on equity of 97.13%. What other stocks do shareholders of Albireo Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Albireo Pharma investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW) and Devon Energy (DVN). Company Calendar Last Earnings11/04/2021Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALBO CIK1322505 Webwww.albireopharma.com Phone(857) 254-5555Fax203-796-5001Employees130Year Founded2003Profitability EPS (Trailing Twelve Months)($6.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.03 million Net Margins-228.51% Pretax Margin-235.11% Return on Equity-97.13% Return on Assets-46.89% Debt Debt-to-Equity RatioN/A Current Ratio6.32 Quick Ratio6.23 Sales & Book Value Annual Sales$40.58 million Price / Sales22.52 Cash FlowN/A Price / Cash FlowN/A Book Value$9.11 per share Price / Book4.85Miscellaneous Outstanding Shares20,700,000Free Float19,273,000Market Cap$913.91 million OptionableOptionable Beta1.03 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ALBO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Albireo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Albireo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.